Evidence map›Paper›PMID 37359549›Full record

ReviewFrontiers in immunology2023

The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions.

Valentina Carlini, Douglas M Noonan, Eslam Abdalalem, Delia Goletti, Clementina Sansone, Luana Calabrone, Adriana Albini

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07139184 (Risk Factor Analysis for Charcot Foot in Patients With Diabetes Mellitus), which is not on this map. Cited by 324 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
324citing papers in PubMed, 2 pooled it
65.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07139184 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Risk Factor Analysis for Charcot Foot in Patients With Diabetes Mellitus: The Interplay of Inflammatory Cytokines and Metabolic Factors

TypeobservationalSponsorAssiut UniversityRan2025 to 2027Enrolled60ConditionsCharcot FootArmsDiagnosis of Charcot foot disease, Hematologic and biochemical parameters,, ELIZA Assay
3 · Its place in the literature

Who cites it

324 citing papers in PubMed, 2 syntheses or guidelines pooled it, 428 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Predictive biomarkers of placebo response in patients with cancer: an exploratory analysis of the ABCD randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

264 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Valentina CarliniIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy.
Douglas M NoonanIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy.
Eslam AbdalalemIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy.
Delia GolettiTranslational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Clementina SansoneStazione Zoologica Anton Dohrn, Istituto Nazionale di Biologia, Ecologia e Biotecnologie Marine, Napoli, Italy.
Luana CalabroneIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy.
Adriana AlbiniIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) European Institute of Oncology IEO-, Milan, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITMultiMedica · ITStazione Zoologica Anton Dohrn · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-10 (IL-10) is a pleiotropic cytokine that has a fundamental role in modulating inflammation and in maintaining cell homeostasis. It primarily acts as an anti-inflammatory cytokine, protecting the body from an uncontrolled immune response, mostly through the Jak1/Tyk2 and STAT3 signaling pathway. On the other hand, IL-10 can also have immunostimulating functions under certain conditions. Given the pivotal role of IL-10 in immune modulation, this cytokine could have relevant implications in pathologies characterized by hyperinflammatory state, such as cancer, or infectious diseases as in the case of COVID-19 and Post-COVID-19 syndrome. Recent evidence proposed IL-10 as a predictor of severity and mortality for patients with acute or post-acute SARS-CoV-2 infection. In this context, IL-10 can act as an endogenous danger signal, released by tissues undergoing damage in an attempt to protect the organism from harmful hyperinflammation. Pharmacological strategies aimed to potentiate or restore IL-10 immunomodulatory action may represent novel promising avenues to counteract cytokine storm arising from hyperinflammation and effectively mitigate severe complications. Natural bioactive compounds, derived from terrestrial or marine photosynthetic organisms and able to increase IL-10 expression, could represent a useful prevention strategy to curb inflammation through IL-10 elevation and will be discussed here. However, the multifaceted nature of IL-10 has to be taken into account in the attempts to modulate its levels.

Indexed as

COVID-19NeoplasmsCytokinesHumansInflammationInterleukin-10Post-Acute COVID-19 SyndromeSARS-CoV-2CytokinesInterleukin-10alarminCOVID - 19cytokine stormIL-10Post-COVIDSTAT3

Identifiers

PMID37359549
PMCPMC10287165
OpenAlexW4380049982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.